The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures

European Journal of Neurology

Volumn 16, Issue 1, 2009, Pages 134-141

  Liimatainen, S ^a   Peltola, M ^a   Fallah, M ^a,b   Kharazmi, E ^a,b   Haapala, A M ^c   Peltola, J ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c PIRKANMAA HOSPITAL DISTRICT   (Finland)

Author keywords

Anticardiolipin antibody; Antinuclear antibody; Antiphospholipid antibody; Recurrent seizure; Refractory focal epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; ANTINUCLEAR ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FOCAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; SEIZURE; SEROPREVALENCE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; COMORBIDITY; EPILEPSIES, PARTIAL; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 57449118906     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02373.x     Document Type: Article

References (41)

1. Aarli JA. Immunological aspects in epilepsy. Brain & Development 1993 15 : 41 50.
2. Aarli JA. Epilepsy and the immune system. Archives of Neurology 2000 57 : 1689 1692.
3. Cole AJ. Is epilepsy a progressive disease? The neurobiological consequences of epilepsy. Epilepsia 2000 41 : S13 S22.
4. Palace J, Lang B. Epilepsy: an autoimmune disease? Journal of Neurology, Neurosurgery and Psychiatry 2000 69 : 711 714.
5. Jankowsky JL, Patterson PH. The role of cytokines and growth factors in seizures and their sequelae. Progress in Neurobiology 2001 63 : 125 149.
6. Crespel A, Coubes P, Rousset MC, et al. Inflammatory reactions in human medial temporal lobe epilepsy with hippocampal sclerosis. Brain Research 2002 18 : 159 169.
7. Pitkänen A, Sutula TP. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal lobe epilepsy. Lancet Neurology 2002 1 : 173 181.
8. Vezzani A, Peltola JT, Janigro D. Inflammation. In : Engel J Jr., Pedley T eds. Epilepsy: A Comprehensive Textbook, 2nd edn. Philadelphia : Lippincott Williams & Wilkins, 2008 : 267 275.
9. Hulkkonen J, Koskikallio E, Rainesalo S, Keränen T, Hurme M, Peltola J. The balance of inhibitory and excitatory cytokines is differently regulated in vivo and in vitro among therapy resistant epilepsy patients. Epilepsy Research 2004 59 : 199 205.
10. Wallenstein MC. Attenuation of penicillin models of epilepsy by nonsteroidal anti-inflammatory drugs. Experimental Neurology 1987 98 : 152 160.
11. van Engelen BG, Renier WO, Weemaes CM. Immunoglobulin treatment in human and experimental epilepsy. Journal of Neurology, Neurosurgery and Psychiatry 1994 57 (Suppl. 72 75.
12. Srivastava AK, Gupta YK. Aspirin modulates the anticonvulsant effect of diazepam and sodium valproate in pentylenetetrazole and maximal electroshock induced seizures in mice. Indian Journal of Physiology & Pharmacology 2001 45 : 475 480.
13. Rogers SW, Andrews PI, Gahring LC, et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994 29 : 648 651.
14. Verrot D, San-Marco M, Dravet C, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. American Journal of Medicine 1997 10 : 33 37.
15. Cimaz R, Romeo A, Scarano A, et al. Prevalence of anti-cardiolipin, anti-beta2 glycoprotein I, and anti-prothrombin antibodies in young patients with epilepsy. Epilepsia 2002 43 : 52 59.
16. Peltola JT, Haapala AM, Isojärvi J, et al. Antiphosholipid and antinuclear antibodies in epileptic syndromes and newly onset seizure disorders. American Journal of Medicine 2000 109 : 712 717.
17. Ranua J, Luoma K, Peltola J, et al. Anticardiolipin and antinuclear antibodies in adult patients with epilepsy - a population based cross-sectional study. Epilepsy Research 2004 58 : 13 18.
18. Sheng JG, Boop FA, Mrak RE, Griffin WS. Increased neuronal beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with interleukin-1 alpha immunoreactivity. Journal of Neurochemistry 1994 63 : 1872 1879.
19. Giometto B, Nicolao P, Macucci M, Tavolato B, Foxon R, Bottazzo GF. Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase autoantibodies. Lancet 1998 8 : 457.
20. Ravizza T, Gagliardi B, Noé F, Boer K, Aronica E, Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiology of Disease 2008 29 : 142 160.
21. Kwan P, Brodie MJ. Early identification of refractory epilepsy. New England Journal of Medicine 2000 342 : 314 319.
22. Kwan P, Brodie MJ. Refractory epilepsy: a progressive, intractable but preventable condition? Seizure 2002 211 : 77 84.
23. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989 30 : 389 399.
24. Commission on Neuroimaging of the International League Against Epilepsy. Recommendations for neuroimaging of patients with epilepsy. Epilepsia 1997 38 : 1255 1256.
25. Eriksson K, Peltola J, Keränen T, Haapala AM, Koivikko M. High prevalence of antiphospholipid antibodies in children; a controlled study of 50 patients. Epilepsy Research 2001 46 : 129 137.
26. Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis & Rheumatism 1994 37 : 568 571.
27. Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. Neurology 2004 23 : 1808 1812.
28. Angelini L, Granata T, Zibordi F, Binelli S, Zorzi G, Besana C. Partial seizures associated with antiphospholipid antibodies in childhood. Neuropediatrics 1998 29 : 249 253.
29. Levite M. Autoimmune epilepsy. Nature Immunology 2002 3 : 500.
30. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005 46 : 1724 1743.
31. Peltola J, Kulmala J, Isojärvi J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000 12 : 46 50.
32. Vincent A, Buckley C, Schott JM. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004 127 : 701 712.
33. Bien CG, Urbach H, Schramm J, et al. Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy. Neurology 2007 18 : 1236 1244.
34. Kent M, Alvarez F, Vogt E, Fyffe R, Ng AK, Rote N. Monoclonal antiphosphatidylserine antibodies react directly with feline and murine central nervous system. Journal of Rheumatology 1997 24 : 1725 1733.
35. 2- glycoprotein I antibodies bind to central nervous system. Journal of Neurological Sciences 1998 156 : 211 219.
36. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilitize and depolarize brain synaptoneurosomes. Lupus 1999 8 : 127 133.
37. Hess D, Sheppard JC, Adams RJ. Increased immunoglobulin binding to cerebral endothelium in patients with antiphospholipid antibodies. Stroke 1993 24 : 994 999.
38. Lolli F, Matá S, Baruffi MC, Amaducci L. Cerebrospinal fluid anti-cardiolipin antibodies in neurological diseases. Clinical Immunology and Immunopathology 1991 59 : 314 321.
39. Yeh TS, Wang CR, Jeng GW, et al. The study of anticardiolipin antibodies and interleukin-6 in cerebrospinal fluid and blood of Chinese patients with systemic lupus erythematosus and central nervous system involvement. Autoimmunity 1994 18 : 169 175.
40. Esch T, Stefano G. Proinflammation: a common denominator or initiator of different pathophysiological disease processes. Medical Science Monitor 2002 8 : HY1 HY9.
41. De Ponti F, Lecchini S, Cosentino M, et al. Immunological adverse effects of anticonvulsants. What is their clinical relevance? Drug Safety 1993 8 : 235 250.